Rovalpituzumab tesirine - Stemcentrx
Alternative Names: Rova-T; SC16LD6.5Latest Information Update: 05 Nov 2023
At a glance
- Originator Stemcentrx
- Developer Bristol-Myers Squibb; Stemcentrx
- Class Antineoplastics; Benzodiazepines; Drug conjugates; Immunoconjugates; Monoclonal antibodies; Pyrroles
- Mechanism of Action DNA damage stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Small cell lung cancer; Solid tumours
Most Recent Events
- 29 May 2020 Updated efficacy and safety data from a phase I/II trial in Solid tumours presented at the 56th Annual Meeting of the American Society of Clinical Oncology (ASCO-2020)
- 27 Sep 2019 Efficacy and safety data from a phase I trial in Small cell lung cancer was presented at the 44th European Society for Medical Oncology Congress (ESMO-2019)
- 29 Aug 2019 Discontinued - Phase-III for Small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Bulgaria, China (IV)